FDA’s QMSR Could Open the Door to More U.S.-LATAM Device Trials
The FDA’s Quality Management System Regulation is being seen as a potential catalyst for more device trial collaboration between the U.S. and Latin America. By harmonizing expectations, it could make cross-border development easier for medtech companies.
The FDA’s Quality Management System Regulation may sound procedural, but its implications are strategic. If the rule helps align expectations across regions, it could reduce friction for medtech companies looking to run trials or build development programs that span the U.S. and Latin America.
That matters because device innovation increasingly depends on geographically distributed clinical evidence. Companies want access to diverse patient populations, faster enrollment, and lower development costs, while regulators want confidence that manufacturing and quality systems can support safe, reproducible products.
The potential upside is significant for Latin American research ecosystems, which could gain more opportunities to participate in device development rather than serving only as downstream markets. More integrated trial networks could also help companies generate data that better reflects real-world variation across populations.
Still, harmonization is not the same as simplicity. Even with a more aligned quality framework, sponsors will need to navigate local regulatory differences, site capabilities, and operational capacity. The real test of QMSR will be whether it lowers enough friction to turn theoretical cross-border collaboration into routine practice.